Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.

"Declarations Ethics approval and consent to participateThe human study protocols followed all relevant ethical regulations in accordance with the Declaration of Helsinki principles. Fresh tumor tissues were obtained after surgery or core needle biopsy within two institutional review board-approved, ethics committee-approved precision medicine studies (STING, NCT0493252; MATCH-R, NCT02517892). All patients signed informed consent. Consent for publicationThe patient whose case is presented signed the MATCH-R trial consent form (NCT02517892). Competing interestsF.J and J.C are co-founders of ORAKL Oncology. The authors declare that they have no competing interests. Competing interests F.J and J.C are co-founders of ORAKL Oncology. The authors declare that they have no competing interests."

"Funding This work was supported by Agence Nationale de la Recherche (ANR) grant ANR-20-CE13-0031–01, Institut National du Cancer (INCa) grant 2020–1-PLBIO-04-IGR-1, Fundraising against CRC and Mars Bleu from the Gustave Roussy foundation and financial support from Inserm Cancer. This work has also benefited from a government grant managed by the National Research Agency under the 5th PIA, integrated into France 2030 with the reference ANR-21-RHUS-0005."